Results 41 to 50 of about 1,759,507 (251)

HIV-1 latency reversal agent boosting is not limited by opioid use

JCI Insight, 2023
Abstract The opioid epidemic may impact the HIV-1 reservoir and its reversal from latency in virally suppressed people with HIV (PWH). We studied forty-seven PWH and observed that lowering the concentration of HIV-1 latency reversal agents (LRA), used in combination with small molecules that do not reverse latency ...
Tyler Lilie, Jennifer Bouzy, Archana Asundi, Jessica Taylor, Samantha Roche, Alex Olson, Kendyll Coxen, Heather Corry, Hannah Jordan, Kiera Clayton, Nina Lin, Athe Tsibris   +11 more
openaire   +3 more sources

Pathways towards human immunodeficiency virus elimination

EBioMedicine, 2020
Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents.
Prasanta K. Dash, Bhavesh D. Kevadiya, Hang Su, Mary G. Banoub, Howard E. Gendelman   +4 more
doaj   +1 more source

Optimal control of an HIV model with gene therapy and latency reversing agents

, 2022
In this project, we study the dynamics of HIV under gene therapy and latency reversing agents. For constant treatment controls, we establish global stability of the disease-free equilibrium and endemic equilibrium based on the value of the basic ...
Hazelton, Paul, Grant, Andrew, Grant, Andrew B   +2 more
core   +1 more source

The role of latency reversal agents in the cure of HIV: A review of current data [PDF]

Immunology Letters, 2018
The definitive cure for human immunodeficiency virus type-1 (HIV) infection is represented by the eradication of the virus from the patient's body. To reach this result, cells that are infected but do not produce the virus must become recognizable to be killed by the immune system.
Bashiri, Kiandokht, Rezaei, Nima, Nasi, Milena, Cossarizza, Andrea   +3 more
openaire   +3 more sources

Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo develop a population pharmacokinetic model for romidepsin given as an HIV latency reversing agent (LRA) and to explore the relationship between romidepsin exposure and its in vivo effects on viral gene expression and antiviral immunity.MethodsA population pharmacokinetic analysis was performed in 15 HIV-1-infected patients who ...
José Moltó, Miriam Rosás-Umbert, Cristina Miranda, Christian Manzardo, Maria C Puertas, Marta Ruiz-Riol, Miriam López, Jose M Miró, Javier Martinez-Picado, Bonaventura Clotet, Christian Brander, Beatriz Mothe, Marta Valle   +12 more
openaire   +3 more sources

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling

International Journal of Molecular Sciences, 2023
Latent HIV is a key factor that makes AIDS difficult to cure. Highly effective and specific latent HIV activators can effectively activate latent HIV, and then combined with antiretroviral therapy to achieve a functional cure of AIDS. Here, four sesquiterpenes (1–4) including a new one (1), five flavonoids (5–9) including three biflavonoid structures ...
Shifei Li, Xiuyi Wang, Yuqin Yang, Xingkang Wu, Liwei Zhang   +4 more
openaire   +2 more sources

Engineering CAR T Cells to Target the HIV Reservoir

Frontiers in Cellular and Infection Microbiology, 2020
The HIV reservoir remains to be a difficult barrier to overcome in order to achieve a therapeutic cure for HIV. Several strategies have been developed to purge the reservoir, including the “kick and kill” approach, which is based on the notion that ...
Wenli Mu, Mayra A. Carrillo, Scott G. Kitchen   +2 more
doaj   +1 more source

PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element

Cells, 2022
At present, the barrier to HIV-1 functional cure is the persistence of HIV-1 reservoirs. The “shock (reversing latency) and kill (antiretroviral therapy)” strategy sheds light on reducing or eliminating the latent reservoir of HIV-1. However, the current
Xinfeng Xu, Yingtong Lin, Xiaoyun Zeng, Chan Yang, Siqin Duan, Liqiong Ding, Wanzhen Lu, Jian Lin, Xiaoyan Pan, Xiancai Ma, Shuwen Liu   +10 more
doaj   +1 more source

Lnc(ing)RNAs to the “shock and kill” strategy for HIV-1 cure

Molecular Therapy: Nucleic Acids, 2021
The advent of antiretroviral therapy almost 25 years ago has transformed HIV-1 infection into a manageable chronic condition, albeit still incurable. The inability of the treatment regimen to eliminate latently infected cells that harbor the virus in an ...
Saikat Boliar, David G. Russell
doaj   +1 more source

Reversing HIV latency via sphingosine-1-phosphate receptor 1 signaling

, 2017
International audienceIn this study, we looked for a new family of latency reversing ...
Campos, Noëlie, Pierre Corbeau, Maurel, Damien, Sandrine Gimenez, Comps-Agrar, Laetitia, Prézeau, Laurent, Etienne Doumazane, Laetitia Comps-Agrar, Gimenez, Sandrine, Clément Mettling, Benjamin Viala, Caroline Boulouis, Laurent Prézeau, Duquenne, Charline, Charline Duquenne, Jamal Tazi, Boulouis, Caroline, Psomas, Christina, François, Vincent, Noëlie Campos, Doumazane, Etienne, Damien Maurel, Viala, Benjamin, Guigues, Adeline, Tazi, Jamal, Corbeau, Pierre, Vincent François, Christina Psomas, Adeline Guigues, Mettling, Clément   +29 more
core   +1 more source